Activation of murine RNase L by isopolar 2'-phosphonate analogues of 2',5' oligoadenylates. 2006

Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 166 10 Prague 6, Czech Republic.

To determine the influence of methylene group insertion in the internucleotide linkage on the binding process of 2',5'-oligoadenylates to RNase L, a series of 2'-phosphonate-modified trimers and tetramers were synthesized from appropriate monomeric units and evaluated for their ability to bind to murine RNase L. Tetramers pAAXA modified by ribo-, arabino-, or xylo-2'-phosphonate unit X in the third position were capable of binding to RNase L in nanomolar concentrations. The replacement of the first residue (pXAAA), or both the first and the third residues (pXAXA), was also tolerated by the enzyme. In contrast, in all cases, the replacement of the second residue (pAXAA) resulted in the significant decrease of binding ability. Additionally, no more than two phosphonate modifications in the tetramer were allowed to retain the binding affinity to the enzyme. Although all three tetramers pAAXA were found to be potent enzyme binders, only tetramers modified by ribo- and xylo-2'-phosphonate unit X activated the RNase L-catalyzed cleavage of the RNA substrate. Surprisingly, tetramer pAAXA, modified by arabino-2'-phosphonate unit X, did not activate the enzyme and can be considered a potent antagonist. In comparison with their natural counterpart, the phosphonate analogues of the pA4 exhibit superior resistance toward nucleases present in the murine spleen homogenate.

UI MeSH Term Description Entries
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009843 Oligoribonucleotides A group of ribonucleotides (up to 12) in which the phosphate residues of each ribonucleotide act as bridges in forming diester linkages between the ribose moieties.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004722 Endoribonucleases A family of enzymes that catalyze the endonucleolytic cleavage of RNA. It includes EC 3.1.26.-, EC 3.1.27.-, EC 3.1.30.-, and EC 3.1.31.-. Endoribonuclease
D000227 Adenine Nucleotides Adenine Nucleotide,Adenosine Phosphate,Adenosine Phosphates,Nucleotide, Adenine,Nucleotides, Adenine,Phosphate, Adenosine,Phosphates, Adenosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
August 1997, The Journal of biological chemistry,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
August 1997, The Journal of biological chemistry,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
February 2022, Bioorganic & medicinal chemistry,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
January 2012, Bioorganic & medicinal chemistry letters,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
December 2014, Journal of virology,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
January 2003, Nucleosides, nucleotides & nucleic acids,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
September 2023, The Journal of general virology,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
March 2022, Bioorganic & medicinal chemistry,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
October 2003, Cancer research,
Ondrej Pav, and Eva Protivinska, and Martina Pressova, and Michaela Collinsova, and Jiri Jiracek, and Jan Snasel, and Milena Masojidkova, and Milos Budesinsky, and Ivan Rosenberg
September 2010, Antiviral research,
Copied contents to your clipboard!